http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113402390-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-157 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-157 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-12 |
| filingDate | 2021-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113402390-B |
| titleOfInvention | A kind of aspirin drug co-crystal and its preparation method and application |
| abstract | The invention relates to the technical field of drug co-crystals, and specifically discloses aspirin drug co-crystals and a preparation method and application thereof. The aspirin drug co-crystal comprises aspirin and ligustrazine in a molar ratio of 1:1. The preparation method comprises the following steps: adding aspirin and ligustrazine into acetonitrile, stirring and mixing uniformly, filtering, collecting powder, and drying to obtain the aspirin drug co-crystal. The present invention forms a co-crystal between aspirin and ligustrazine, simultaneously solves the problems of poor solubility of aspirin in the stomach, slow dissolution rate, and easy sublimation of ligustrazine, solves the problem of large stimulation of gastric mucosa by aspirin and ligustrazine, and improves both The bioavailability can be used to be developed into various preparations, and it can be used as a new type of drug for anticoagulant, antithrombotic, prevention or treatment of cardiovascular diseases, and has a high application prospect. |
| priorityDate | 2021-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.